

REPLY

In Reply to “Using Immunoglobulin G Spike Antibodies as a Surrogate Marker for Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Additional Considerations”



To the Editor:

As with all retrospective data, there are limitations that Daungsupawong and Wiwanitkit appropriately note.¹ Nevertheless, the use of these data to identify subclinical infections among patients receiving maintenance dialysis is meaningful. As a mandatory congregate population with high comorbid burden, patients receiving maintenance dialysis are particularly vulnerable to coronavirus disease 2019, and some providers may wish to consider the prevalence of subclinical infections in making recommendations for masking and redosing the vaccine. In addition to antibody levels waning over time, vaccine effectiveness has also been observed to wane over time,^{2,3} and a few studies have shown correlation of antibody levels and vaccine effectiveness.^{4,5} We agree that further research is needed, particularly to stay up-to-date with the constantly evolving coronavirus disease 2019 landscape.

Caroline M. Hsu, MD, MS, Daniel E. Weiner, MD, MS,
Harold J. Manley, PharmD, Doug Johnson, MD,
and Eduardo K. Lacson Jr, MD, MPH

ARTICLE INFORMATION

Authors' Affiliations: Tufts Medical Center, Boston, Massachusetts (CMH, DEW, EKL); and Dialysis Clinic Inc, Nashville, Tennessee (HJM, DJ, EKL).

Address for Correspondence: Caroline M. Hsu, MD, MS, 800 Washington St, Box #391, Boston, MA 02111. Email: caroline.hsu1@tuftsmedicine.org

Support: This report was supported by Dialysis Clinic, Inc. CMH has received support from ASN KidneyCure's Ben J. Lipps Research

fellowship and from NIH/NCATS grants KL2TR002545 and 1K12TR004384. CMH's funders had no role in study design, data collection, reporting, or the decision to submit.

Financial Disclosure: Dr Manley, Dr Johnson, and Dr Lacson Jr are all employees of DCI, where Dr Johnson is Vice Chair of the Board. Dr Hsu and Dr Weiner receive salary support to their institution from DCI.

Peer Review: Received November 1, 2023. Accepted after editorial review by an Associate Editor who served as Acting Editor-in-Chief. Accepted in revised form November 15, 2023. The involvement of an Acting Editor-in-Chief was to comply with Kidney Medicine's procedures for potential conflicts of interest for editors, described in the Information for Authors & Journal Policies.

Publication Information: © 2023 The Authors. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>). Published online December 14, 2023 with doi [10.1016/j.xkme.2023.100781](https://doi.org/10.1016/j.xkme.2023.100781)

REFERENCES

1. Daungsupawong H, Wiwanitkit V. Using immunoglobulin G spike antibodies as a surrogate marker for severe acute respiratory syndrome coronavirus 2 infection: additional considerations. *Kidney Med.* 2024;6:100780. doi:[10.1016/j.xkme.2023.100781](https://doi.org/10.1016/j.xkme.2023.100781)
2. Collie S, Nayager J, Bamford L, Bekker LG, Zylstra M, Gray G. Effectiveness and durability of the BNT162b2 vaccine against omicron sublineages in South Africa. *N Engl J Med.* 2022;387(14):1332-1333. doi:[10.1056/NEJMc2210093](https://doi.org/10.1056/NEJMc2210093)
3. Liu B, Stepien S, Dobbins T, et al. Effectiveness of COVID-19 vaccination against COVID-19 specific and all-cause mortality in older Australians: a population based study. *Lancet Reg Health West Pac.* 2023;40:100928. doi:[10.1016/j.lanwpc.2023.100928](https://doi.org/10.1016/j.lanwpc.2023.100928)
4. Manley HJ, Li NC, Aweh GN, et al. SARS-CoV-2 vaccine effectiveness and breakthrough infections among patients receiving maintenance dialysis. *Am J Kidney Dis.* 2023;81(4):406-415. doi:[10.1053/j.ajkd.2022.10.010](https://doi.org/10.1053/j.ajkd.2022.10.010)
5. Earle KA, Ambrosino DM, Fiore-Gartland A, et al. Evidence for antibody as a protective correlate for COVID-19 vaccines. *Vaccine.* 2021;39(32):4423-4428. doi:[10.1016/j.vaccine.2021.05.063](https://doi.org/10.1016/j.vaccine.2021.05.063)